2022年5月18日 · The AViDD Centers will conduct innovative, multidisciplinary research to develop candidate COVID-19 antivirals, especially those that can be taken in an outpatient setting, as well as antivirals targeting specific viral families with high potential to cause a pandemic in the future.

2022年5月26日 · As part of the APP effort in 2022, NIAID awarded approximately $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

Our mission at the Midwest Antiviral Drug Discovery (AViDD) Center is to quickly develop the next generation of antiviral drugs for pandemic-level viruses, including SARS-CoV-2, Ebola, Lassa and Zika viruses. The Center is part of a network of nine national centers established by the National Institute of Allergy and Infectious Diseases (NIAID).

The QCRG AViDD Program will discover and develop inhibitors targeting key viral proteins. Innovation comes from using cutting-edge techniques individually and in combination with each other as well as from the viral proteins and processes targeted (e.g., viral enzymes that act to suppress host immune response).

2022年5月18日 · The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

2022年5月18日 · The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

2022年5月18日 · The Antiviral Countermeasures Development Center (AC/DC) is one of nine Antiviral Drug Discovery (AViDD) Centers around the country being funded by the National Institute of Allergy and Infectious Diseases (NIAID).

2022年5月18日 · The award, the largest in UCSF’s history, establishes one of nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern across the country. These will be collaborative, multidisciplinary academic-industry research centers to develop candidate antivirals for COVID-19 and other viruses with pandemic potential.

The QCRG AViDD Program will discover and develop inhibitors targeting key viral proteins. Innovation comes from using cutting-edge techniques individually and in combination with each other as well as from the viral proteins and processes targeted (e.g., viral enzymes that act to suppress host immune response).

2022年5月18日 · The AViDD centers will conduct innovative, multidisciplinary research to develop candidate COVID-19 antivirals, especially those that can be taken in an outpatient setting, as well as antivirals...